Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if low bone mineral density (a measurement of how
thick and strong bones are) improves in adults with HIV infection who switch their HIV
medication tenofovir to another HIV medication raltegravir.
Hypothesis:That Bone Mineral Density (BMD) will improve in osteopenic or osteoporotic
patients switching from ART including tenofovir disoproxil fumarate (TDF) and a
ritonavir-boosted protease inhibitor (r/PI) to ART including RAL+r/PI.
Phase:
Phase 4
Details
Lead Sponsor:
St Vincent's Hospital, Sydney
Collaborators:
Holdsworth House Medical Practice Merck Sharp & Dohme Corp. The Alfred